MCID: BRD004
MIFTS: 51

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 76 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD10 33 F60.3
ICD9CM 35 301.83
MeSH 44 D001883
NCIt 50 C92633
SNOMED-CT 68 20010003
UMLS 73 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to personality disorder and alexithymia. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Citalopram and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and testes, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 76 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 personality disorder 30.9 TPH1 SLC6A4 MAOA HTR2C HTR2A HTR1B
2 alexithymia 30.7 COMT HTR1A SLC6A4
3 antisocial personality disorder 30.4 COMT HTR1B MAOA SLC6A4
4 bulimia nervosa 30.4 BDNF COMT HTR1B HTR2A SLC6A4
5 eating disorder 30.4 BDNF COMT HTR2C SLC6A4
6 substance dependence 30.3 BDNF HTR1B MAOA SLC6A4
7 conduct disorder 30.3 COMT MAOA SLC6A4 TPH1
8 dysthymic disorder 30.3 HTR2A MAOA SLC6A4
9 alcohol abuse 30.2 BDNF HTR2A SLC6A4
10 atypical depressive disorder 30.1 HTR2A MAOA SLC6A4
11 schizoaffective disorder 30.1 BDNF COMT HTR2A SLC6A4
12 anorexia nervosa 30.1 BDNF COMT HTR2A SLC6A4
13 substance abuse 30.0 BDNF COMT HTR1B MAOA SLC6A4
14 intermittent explosive disorder 30.0 HTR1A SLC6A4
15 avoidant personality disorder 30.0 MAOA SLC6A4 TPH1
16 depression 29.9 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
17 social phobia 29.9 HTR1A MAOA SLC6A4
18 fibromyalgia 29.9 COMT HTR2A SLC6A4
19 post-traumatic stress disorder 29.9 BDNF COMT HTR2A MAOA NR3C1 SLC6A4
20 asperger syndrome 29.8 AVPR1A BDNF SLC6A4
21 oppositional defiant disorder 29.7 COMT MAOA SLC6A4 TPH2
22 bipolar disorder 29.6 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
23 bipolar i disorder 29.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
24 attention deficit-hyperactivity disorder 29.5 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
25 disease of mental health 29.5 BDNF COMT HTR1A HTR2A HTR2C MAOA
26 schizophrenia 29.4 BDNF COMT HTR1A HTR1B HTR2A HTR2C
27 psychotic disorder 29.4 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
28 anxiety 29.3 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
29 generalized anxiety disorder 29.3 BDNF COMT HTR1A HTR2A MAOA SLC6A4
30 endogenous depression 29.1 TPH1 SLC6A4 NR3C1 MAOA HTR2A HTR1A
31 major depressive disorder 29.1 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
32 mood disorder 29.0 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
33 chronic fatigue syndrome 29.0 COMT HTR1A HTR2A MAOA NR3C1 SLC6A4
34 mental depression 29.0 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR2C
35 panic disorder 29.0 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
36 obsessive-compulsive disorder 28.7 TPH2 TPH1 SLC6A4 MAOA HTR2C HTR2A
37 alcohol dependence 28.0 TPH2 TPH1 SLC6A4 NRXN3 MAOA HTR2C
38 multiple personality disorder 11.4
39 impulse control disorder 11.0
40 bronchopulmonary dysplasia 10.5
41 cognitive function 1, social 10.3
42 sexual disorder 10.2 HTR1A SLC6A4
43 phobia, specific 10.2 COMT MAOA
44 schizophrenia 5 10.2 COMT HTR2A
45 early-onset schizophrenia 10.2 BDNF HTR2A
46 alcoholic psychosis 10.2 HTR2A SLC6A4
47 tic disorder 10.2 HTR2A TPH2
48 tardive dyskinesia 10.2 COMT HTR2A
49 schizoid personality disorder 10.2 HTR1A HTR2A
50 hypoactive sexual desire disorder 10.2 HTR1A HTR2A

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
2 cardiovascular system MP:0005385 10.02 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
3 homeostasis/metabolism MP:0005376 9.96 AVPR1A BDNF COMT HTR1A HTR2C MAOA
4 endocrine/exocrine gland MP:0005379 9.87 AVPR1A BDNF COMT HTR1B HTR2A NR3C1
5 adipose tissue MP:0005375 9.83 HTR1B HTR2C NR3C1 TPH1 TPH2
6 integument MP:0010771 9.63 BDNF HTR2C NR3C1 SLC6A4 TPH1 TPH2
7 muscle MP:0005369 9.5 AVPR1A HTR1B HTR2A HTR2C NR3C1 SLC6A4
8 nervous system MP:0003631 9.28 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
2
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
3
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6 Omega 3 Fatty Acid Phase 4
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
11 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
12 Antidepressive Agents Phase 4,Phase 2,Not Applicable
13 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Parasympatholytics Phase 4,Phase 2,Not Applicable
16 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
17 Cholinergic Antagonists Phase 4,Phase 2,Not Applicable
18 Muscarinic Antagonists Phase 4,Phase 2,Not Applicable
19 Cholinergic Agents Phase 4,Phase 2,Not Applicable
20 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Dopamine Agents Phase 4,Phase 2,Not Applicable
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
24 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Serotonin Antagonists Phase 4,Phase 2,Not Applicable
26 Dopamine Antagonists Phase 4,Phase 2,Not Applicable
27 Calcium, Dietary Phase 4
28 Diuretics, Potassium Sparing Phase 4
29 Excitatory Amino Acid Antagonists Phase 4,Phase 2
30 Sodium Channel Blockers Phase 4
31 calcium channel blockers Phase 4
32 Excitatory Amino Acids Phase 4,Phase 2
33 Anticonvulsants Phase 4,Phase 3,Not Applicable
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
37
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
38
Ethanol Approved Phase 3,Phase 2,Not Applicable 64-17-5 702
39
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
40
Olanzapine Approved, Investigational Phase 3,Not Applicable 132539-06-1 4585
41 Narcotics Phase 3,Phase 2,Not Applicable
42 Narcotic Antagonists Phase 3,Phase 2,Not Applicable
43 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
44 Antiemetics Phase 3,Not Applicable
45 Gastrointestinal Agents Phase 3,Not Applicable
46 Analgesics, Opioid Phase 3,Not Applicable
47 Protective Agents Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents, Local Phase 3,Phase 2
49 Anti-Infective Agents Phase 3,Phase 2,Phase 1
50
Acetaminophen Approved Phase 2 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
10 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
11 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
12 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
13 The Short-Term MBT Project Recruiting NCT03677037 Phase 3
14 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
15 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
16 Acetaminophen and Social Processes Unknown status NCT02108990 Phase 2 Acetaminophen
17 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
18 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
19 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
20 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
21 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
22 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
23 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
24 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
25 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
26 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
27 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
28 Brexpiprazole in Borderline Personality Disorder Recruiting NCT03418675 Phase 2 Rexulti;Placebo
29 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
30 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
31 Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
32 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Recruiting NCT01212588 Phase 2 mifepristone;Placebo
33 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
34 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
35 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
36 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
37 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
38 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
39 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
40 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
41 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497 Not Applicable
42 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
43 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634 Not Applicable
44 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 Not Applicable guanfacine (Tenex)
45 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708 Not Applicable
46 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781 Not Applicable
47 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 Not Applicable methylphenidate
48 DBT in Borderline Personality Disorder Unknown status NCT00252031 Not Applicable
49 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554 Not Applicable Escitalopram
50 Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD Unknown status NCT02134223 Not Applicable

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

41
Brain, Amygdala, Testes, Skin, Cortex, Pituitary, Ovary

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 1626)
# Title Authors Year
1
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
2
Psychotic symptoms in borderline personality disorder: an update. ( 30169467 )
2019
3
Borderline personality disorder traits and suicide risk: The mediating role of insomnia and nightmares. ( 30326346 )
2019
4
Exclusion-Proneness in Borderline Personality Disorder Inpatients Impairs Alliance in Mentalization-Based Group Therapy. ( 29910754 )
2018
5
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
6
Positive psychotic symptoms in patients with borderline personality disorder: a valuable but still not completely understood clinical marker of the illness. ( 29873564 )
2018
7
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. ( 29847836 )
2018
8
Individuals with Borderline Personality Disorder manifest cognitive biases implicated in psychosis. ( 29960939 )
2018
9
Sensitization of the Neural Salience Network to Repeated Emotional Stimuli Following Initial Habituation in Patients With Borderline Personality Disorder. ( 29961363 )
2018
10
Training in Good Psychiatric Management for Borderline Personality Disorder in Residency: An Aide to Learning Supportive Psychotherapy for Challenging-to-Treat Patients. ( 29809114 )
2018
11
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
12
Erratum - Borderline Personality Disorder Symptom Severity and Sexually Transmitted Infection and HIV Risk in African American Incarcerated Men. ( 29889162 )
2018
13
Borderline personality disorder is equally trait-like and state-like over ten years in adult psychiatric patients. ( 29952598 )
2018
14
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
15
The Endocannabinoid System, Aggression, and the Violence of Synthetic Cannabinoid Use, Borderline Personality Disorder, Antisocial Personality Disorder, and Other Psychiatric Disorders. ( 29636670 )
2018
16
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
17
Abnormal Sensitization of Neural and Behavioral Responses to Socially Relevant Images in Individuals With Borderline Personality Disorder: Implications for Guiding More Effective Targeting of Treatments. ( 29961366 )
2018
18
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
19
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
20
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
21
Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System. ( 29860953 )
2018
22
Dissecting the elements of borderline personality disorder. ( 29878704 )
2018
23
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
24
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
25
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
26
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
27
Psychiatrists' motives for practising in-patient compulsory care of patients with borderline personality disorder (BPD). ( 29853014 )
2018
28
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
29
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
30
Treatment of a Patient with Borderline Personality Disorder Based on Phase-Oriented Model of Eye Movement Desensitization and Reprocessing (EMDR): A Case Report. ( 29892320 )
2018
31
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
32
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. ( 29949444 )
2018
33
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
34
Partners of Individuals with Borderline Personality Disorder: A Systematic Review of the Literature Examining Their Experiences and the Supports Available to Them. ( 29975337 )
2018
35
Emotional responses to receiving peer feedback on opinions in borderline personality disorder. ( 29927294 )
2018
36
The rewarding nature of provocation-focused rumination in women with borderline personality disorder: a preliminary fMRI investigation. ( 29372058 )
2018
37
Book Review: Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods . Livesley W. John . Cambridge (UK) : Cambridge University Press ; 2017 . 297 p. US$66.50 . Paperback. ISBN 978-1-10-67974-0 . Reviewer rating: Excellent. ( 29433334 )
2018
38
Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. ( 29402870 )
2018
39
Symptom, alexithymia and self-image outcomes of Mentalisation-based treatment for borderline personality disorder: a naturalistic study. ( 29890960 )
2018
40
Assessing advanced theory of mind and alexithymia in patients suffering from enduring borderline personality disorder. ( 29360051 )
2018
41
Men and women with borderline personality disorder resident in Dutch special psychiatric units in prisons: A descriptive and comparative study. ( 29971844 )
2018
42
Treating borderline personality disorder with oxytocin: An enthusiastic note of caution. Commentary to Servan et al. The effect of oxytocin in borderline personality disorder. ( 29402386 )
2018
43
Affect dysregulation, psychoform dissociation, and adult relational fears mediate the relationship between childhood trauma and complex posttraumatic stress disorder independent of the symptoms of borderline personality disorder. ( 29410773 )
2018
44
Borderline personality disorder features and drinking, cannabis, and prescription opioid motives: Differential associations across substance and sex. ( 29945027 )
2018
45
Attachment-Related Regulatory Processes Moderate the Impact of Adverse Childhood Experiences on Stress Reaction in Borderline Personality Disorder. ( 29388902 )
2018
46
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
47
Alexithymia in borderline personality disorder is not associated with deficits in automatic visual processing of negative emotional stimuli. ( 29547729 )
2018
48
Cognitive distortions in anorexia nervosa and borderline personality disorder. ( 29197752 )
2018
49
Please Don't Leave Me-Separation Anxiety and Related Traits in Borderline Personality Disorder. ( 30155649 )
2018
50
Do borderline personality disorder and attention-deficit/hyperactivity disorder co-aggregate in families? A population-based study of 2 million Swedes. ( 30323291 )
2018

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
2 12.27 COMT HTR1A TPH1 TPH2
4
Show member pathways
12.03 BDNF HTR1A HTR1B
5
Show member pathways
11.98 AVPR1A HTR2A HTR2C
6 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
7
Show member pathways
11.93 MAOA TPH1 TPH2
8
Show member pathways
11.68 HTR1A HTR1B HTR2A HTR2C
9 11.62 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
10
Show member pathways
11.21 MAOA SLC6A4 TPH2
11
Show member pathways
11.18 TPH1 TPH2
12
Show member pathways
10.99 TPH1 TPH2
13
Show member pathways
10.96 COMT MAOA SLC6A4
14 10.8 HTR2A HTR2C
15
Show member pathways
10.78 COMT MAOA TPH1
16 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
17
Show member pathways
10.65 COMT MAOA
18 10.6 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.7 AVPR1A HTR1A HTR1B HTR2A HTR2C NRXN3
2 integral component of presynaptic membrane GO:0099056 9.43 HTR1B HTR2A SLC6A4
3 dendrite GO:0030425 9.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
4 serotonergic synapse GO:0099154 8.96 HTR1B SLC6A4

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 circadian rhythm GO:0007623 9.79 SLC6A4 TPH1 TPH2
2 response to drug GO:0042493 9.77 COMT HTR1B HTR2A HTR2C SLC6A4
3 memory GO:0007613 9.74 BDNF HTR2A SLC6A4
4 chemical synaptic transmission GO:0007268 9.72 HTR1A HTR1B HTR2A HTR2C NRXN3
5 social behavior GO:0035176 9.71 AVPR1A NRXN3 SLC6A4
6 positive regulation of fat cell differentiation GO:0045600 9.7 HTR2A HTR2C TPH1
7 release of sequestered calcium ion into cytosol GO:0051209 9.65 HTR2A HTR2C
8 feeding behavior GO:0007631 9.64 HTR1B HTR2C
9 regulation of dopamine secretion GO:0014059 9.64 HTR1B HTR2A
10 behavioral fear response GO:0001662 9.63 HTR1A HTR2C
11 positive regulation of vasoconstriction GO:0045907 9.63 AVPR1A HTR2A
12 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.63 HTR1A HTR1B HTR2A
13 bone remodeling GO:0046849 9.62 HTR1B TPH1
14 catecholamine metabolic process GO:0006584 9.61 COMT MAOA
15 neurotransmitter catabolic process GO:0042135 9.6 COMT MAOA
16 regulation of behavior GO:0050795 9.59 HTR1A HTR1B
17 aromatic amino acid family metabolic process GO:0009072 9.58 TPH1 TPH2
18 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.58 HTR1B HTR2A
19 activation of phospholipase C activity GO:0007202 9.58 AVPR1A BDNF HTR2A
20 dopamine catabolic process GO:0042420 9.56 COMT MAOA
21 sperm ejaculation GO:0042713 9.55 AVPR1A SLC6A4
22 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.51 HTR2A HTR2C
23 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.49 HTR1A HTR1B
24 serotonin biosynthetic process GO:0042427 9.48 TPH1 TPH2
25 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.46 HTR1A HTR1B HTR2A HTR2C
26 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.43 HTR2A HTR2C
27 vasoconstriction GO:0042310 9.43 HTR1A HTR1B SLC6A4
28 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR2C
29 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C
30 signal transduction GO:0007165 10.16 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
31 G protein-coupled receptor signaling pathway GO:0007186 10.04 AVPR1A HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.83 AVPR1A HTR1A HTR1B HTR2A HTR2C
2 drug binding GO:0008144 9.58 HTR1B HTR2A HTR2C
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TPH2
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.32 HTR2A HTR2C
6 tryptophan 5-monooxygenase activity GO:0004510 9.26 TPH1 TPH2
7 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
8 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C SLC6A4

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....